Docoh
Loading...

RGRX Regenerx Biopharmaceuticals

RegeneRx Biopharmaceuticals Inc. (“RegeneRx” or the “Company”) (OTCQB:RGRX) is a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. We have formulated Tß4 into three distinct product candidates in clinical development:

Company profile

Ticker
RGRX
Exchange
CEO
J. J. Finkelstein
Employees
Incorporated
Location
Fiscal year end
Former names
ALPHA 1 BIOMEDICALS INC, ALPHA 1 BIOMEDICALS INC /DE/
SEC CIK
IRS number
521253406

RGRX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

14 May 21
3 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 207.61K 207.61K 207.61K 207.61K 207.61K 207.61K
Cash burn (monthly) 73.43K 33.93K 126.56K 126.36K 80.78K 81.85K
Cash used (since last report) 303.47K 140.23K 523.08K 522.24K 333.85K 338.28K
Cash remaining -95.86K 67.38K -315.46K -314.62K -126.23K -130.67K
Runway (months of cash) -1.3 2.0 -2.5 -2.5 -1.6 -1.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
30 Jun 21 Cavazza Paolo Common Stock Buy Aquire P Yes No 0.2 1,500,000 300K 1,500,000
30 Jun 21 Cavazza Paolo Common Stock Warrant Common Stock Other Aquire J Yes No 0.28 1,125,000 315K 1,125,000
30 Jun 21 Cavazza Paolo Common Stock Warrant Common Stock Other Aquire J Yes No 0.24 1,125,000 270K 1,125,000
30 Jun 21 Goldstein Allan L Common Stock Buy Aquire P No No 0.2 125,000 25K 1,637,793
30 Jun 21 Goldstein Allan L Series B Common Stock Warrant Common Stock Buy Aquire P No No 0.28 93,750 26.25K 93,750
30 Jun 21 Goldstein Allan L Series A Common Stock Warrant Common Stock Buy Aquire P No No 0.24 93,750 22.5K 93,750
30 Jun 21 Finkelstein J J Common Stock Buy Aquire P No No 0.2 75,000 15K 1,712,991
30 Jun 21 Finkelstein J J Series B Common Stock Warrant Common Stock Buy Aquire P No No 0.28 56,250 15.75K 56,250
30 Jun 21 Finkelstein J J Series A Common Stock Warrant Common Stock Buy Aquire P No No 0.24 56,250 13.5K 56,250
13 Feb 20 Goldstein Allan L Common Stock Gift Dispose G No No 0 200,000 0 1,512,793

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

38.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2 1 +100.0%
Opened positions 1 1
Closed positions 0 1 EXIT
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 22.9M 22.85M +0.2%
Total shares 51.73M 51.52M +0.4%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Essetifin SPA 51.52M $22.85M 0.0%
Williams Jones Wealth Management 210K $53K NEW
Largest transactions
Shares Bought/sold Change
Williams Jones Wealth Management 210K +210K NEW
Essetifin SPA 51.52M 0 0.0%

Financial report summary

?
Competition
Kala Pharmaceuticals
Management Discussion
  • This Quarterly Report on Form 10-Q, including this Part I., Item 2., “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words “project,” “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,” “would,” “could,” “will,” “may” or other similar expressions. In addition, any statements that refer to projections of our future financial performance, our clinical development programs and schedules, our future capital resources and funding requirements, our expectations regarding future licenses of our technology, our anticipated growth and trends in our business and other characterizations of future events or circumstances are forward-looking statements. We cannot guarantee that we will achieve the plans, intentions or expectations expressed or implied in our forward-looking statements.  There are a number of important factors that could cause actual results, levels of activity, performance or events to differ materially from those expressed or implied in the forward-looking statements we make, including those described under “Risk Factors” set forth below in Part II., Item 1A. In addition, any forward-looking statements we make in this document speak only as of the date of this report, and we do not intend to update any such forward-looking statements to reflect events or circumstances that occur after that date.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: avoid, corticosteroid, etabonate, Kala, loteprednol, page, personal, resign, suspension, timeline, Topline
Removed: Aid, back, bifurcated, bore, contractor, convert, declared, deferred, derivative, disruption, embedded, involving, Master, matured, newly, NIH, outbreak, reference, Relief, represented, repriced, residual, round, sixty, spread, temporary, Thompson, vial, world